Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sphingosine | 5 | 2022 | 318 | 0.880 |
Why?
|
| Lysophospholipids | 5 | 2022 | 338 | 0.860 |
Why?
|
| Nasal Lavage Fluid | 1 | 2017 | 14 | 0.680 |
Why?
|
| Occupational Exposure | 3 | 2017 | 1775 | 0.610 |
Why?
|
| Isocyanates | 1 | 2013 | 9 | 0.510 |
Why?
|
| Nasal Obstruction | 1 | 2013 | 155 | 0.420 |
Why?
|
| Occupational Diseases | 3 | 2017 | 1462 | 0.390 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 2716 | 0.360 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1948 | 0.340 |
Why?
|
| Respiratory Tract Diseases | 1 | 2013 | 695 | 0.330 |
Why?
|
| Capillary Permeability | 2 | 2022 | 856 | 0.310 |
Why?
|
| Endothelial Cells | 3 | 2022 | 3433 | 0.230 |
Why?
|
| Proteins | 1 | 2017 | 6166 | 0.220 |
Why?
|
| Immune System Phenomena | 1 | 2019 | 16 | 0.200 |
Why?
|
| Receptor Cross-Talk | 1 | 2019 | 124 | 0.180 |
Why?
|
| Rhinitis | 2 | 2017 | 660 | 0.170 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2019 | 242 | 0.170 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2017 | 118 | 0.150 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13754 | 0.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 436 | 0.150 |
Why?
|
| Acute-Phase Proteins | 1 | 2017 | 273 | 0.150 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 4636 | 0.140 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 325 | 0.140 |
Why?
|
| Molecular Chaperones | 1 | 2019 | 759 | 0.130 |
Why?
|
| Skin Tests | 1 | 2017 | 644 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2020 | 1332 | 0.130 |
Why?
|
| Hypochondriasis | 1 | 2013 | 93 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2019 | 770 | 0.120 |
Why?
|
| Fibrosis | 1 | 2019 | 1964 | 0.110 |
Why?
|
| Central Nervous System | 1 | 2019 | 1292 | 0.110 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2006 | 550 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 958 | 0.100 |
Why?
|
| Reperfusion Injury | 1 | 2017 | 1074 | 0.100 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 452 | 0.100 |
Why?
|
| Anxiety Disorders | 2 | 2013 | 2591 | 0.090 |
Why?
|
| Homeostasis | 1 | 2019 | 3344 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2113 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3433 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2020 | 15258 | 0.080 |
Why?
|
| Cell Movement | 1 | 2019 | 5465 | 0.070 |
Why?
|
| Mood Disorders | 1 | 2013 | 1105 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4383 | 0.070 |
Why?
|
| Mice | 4 | 2020 | 81128 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10802 | 0.060 |
Why?
|
| Animals | 6 | 2022 | 170894 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 16989 | 0.060 |
Why?
|
| Cytokines | 1 | 2017 | 7223 | 0.060 |
Why?
|
| Asthma | 3 | 2006 | 5941 | 0.060 |
Why?
|
| Bleomycin | 1 | 2022 | 512 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2019 | 78 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2019 | 23997 | 0.040 |
Why?
|
| Hypertension | 1 | 2017 | 8285 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2022 | 9927 | 0.040 |
Why?
|
| Humans | 11 | 2019 | 717280 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2019 | 726 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2022 | 1115 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2006 | 2754 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 2669 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 14381 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2017 | 563 | 0.030 |
Why?
|
| Adult | 4 | 2017 | 212470 | 0.030 |
Why?
|
| Middle Aged | 4 | 2017 | 215054 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2022 | 2834 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2006 | 3818 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 652 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 22929 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 1207 | 0.030 |
Why?
|
| Male | 5 | 2017 | 351399 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1587 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 2161 | 0.030 |
Why?
|
| Canada | 2 | 2006 | 1957 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2019 | 4329 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9597 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 1671 | 0.020 |
Why?
|
| Quebec | 1 | 2006 | 134 | 0.020 |
Why?
|
| Quality of Life | 1 | 2006 | 11758 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2006 | 369 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 9665 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 16693 | 0.020 |
Why?
|
| Phenotype | 1 | 2022 | 16404 | 0.020 |
Why?
|
| Lung | 1 | 2022 | 9781 | 0.010 |
Why?
|
| Female | 3 | 2017 | 377934 | 0.010 |
Why?
|
| Workers' Compensation | 1 | 2003 | 154 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13605 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 13276 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 14899 | 0.010 |
Why?
|
| Allergens | 1 | 2003 | 1293 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 4321 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 5268 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 11276 | 0.010 |
Why?
|
| Comorbidity | 1 | 2006 | 10452 | 0.010 |
Why?
|
| Air Pollutants | 1 | 2003 | 2625 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 20654 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 23409 | 0.000 |
Why?
|
| Risk Factors | 1 | 2006 | 70863 | 0.000 |
Why?
|
| United States | 1 | 2003 | 67804 | 0.000 |
Why?
|
| Aged | 1 | 2006 | 162862 | 0.000 |
Why?
|
Concepts
(97)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_